IL25 and colorectal carcinoma: Using the Apc-mutant-DSS model of colonic adenocarcinoma (41), our results show that the type 2 immune microenvironment driven by the IL-25-ILC2 axis promotes Apc-mutation-dependent CRC, and therapeutic anti-IL-25R treatment reduced CRC burden.